Russia has collaborated with an Indian firm for Sputnik V trials.

Russia collaborated with Indian pharmaceuticals major Dr. Reddy’s Laboratories to conduct clinical trials and distribute COVID-19 vaccine Sputnik V.

The Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said the collaboration was confirmed on September 16. The RDIF is in talks with Indian regulators to ensure that all the requirements for clinical trials are being met with, he added. Upon regulatory approval in India, the RDIF shall supply Dr. Reddy's 100 million vaccine doses.

The collaboration happened in the backdrop of discussions between Russia's envoy to India, Nikolay Kudashev, and Indian officials to discuss cooperation during the vaccine's joint development and production.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.

Reference links

The Economic Times

supports

Hindustan Times

supports

RDIF

supports

Have a question or correction?

Please tell us if you think this claim had been misjudged or requires correction by sending us evidence to support your error claim. We will revisit our evidence and verdict and do some additional research to double check if we can verify the new information

Fact Check of the Day

false

A video shows people running in fear after firing and blast at the Brooklyn subway, New York.